.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,133,890

« Back to Dashboard

Claims for Patent: 8,133,890

Title:Combination of brimonidine and timolol for topical ophthalmic use
Abstract: Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.
Inventor(s): Chang; Chin-Ming (Tustin, CA), Beck; Gary J. (Fullerton, CA), Pratt; Cynthia C. (Mission Viejo, CA), Batoosingh; Amy L. (Mission Viejo, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:11/946,828
Patent Claims: 1. A method of treating a patient exhibiting elevated intraocular pressure (IOP), the method comprising administering twice daily to an affected eye a composition comprising 0.2% w/v, brimonidine and 0.5% w/v, timolol in a single composition, wherein said method results in a lower incidence of one or more adverse events, as compared to brimonidine in the absence of timolol, where the adverse event is selected from the group consisting of oral dryness, eye pruritus, foreign body sensation, allergic conjunctivitis, somnolence and conjunctival folliculosis.

2. A method according to claim 1, wherein the brimonidine is selected from the group consisting of brimonidine tartrate and brimonidine free base.

3. A method according to claim 1, wherein the timolol is selected from the group consisting of timolol tartrate, timolol maleate and timolol free base.

4. A method according to claim 1, wherein the brimonidine is selected from the group consisting of brimonidine tartrate and brimonidine free base and the timolol is selected from the group consisting of timolol tartrate, timolol maleate and timolol free base.

5. A method according to claim 1, wherein the brimonidine is brimonidine tartrate.

6. A method according to claim 1, wherein the timolol is timolol maleate.

7. A method according to claim 1, wherein the brimonidine is brimonidine tartrate and the timolol is timolol maleate.

8. A method according to claim 1 wherein the composition further comprises benzalkonium chloride.

9. A method according to claim 8 wherein the composition further comprises from 0.001% w/v to less than 0.01% w/v benzalkonium chloride.

10. A method according to claim 9 wherein the composition further comprises about 0.005% w/v benzalkonium chloride.

11. A method according to any one of claims 1, 4, 8 and 9 wherein the adverse event is allergic conjunctivitis.

12. A method according to claim 1, wherein the patient has one or more of ocular hypertension, chronic open-angle glaucoma, chronic angle-closure glaucoma with patent iridotomy, pseudoexfoliative glaucoma or pigmentary glaucoma.

13. A method of reducing elevated intraocular pressure associated with glaucoma or ocular hypertension comprising administering twice daily to an affected eye a single composition comprising both 0.2% w/v brimonidine tartrate and about 0.5% w/v timolol, wherein the method results in a lower incidence of oral dryness, eye pruritus, allergic conjunctivitis, foreign body sensation, somnolence, or conjunctival folliculosis as compared to using 0.2% w/v brimonidine tartrate in the absence of timolol.

14. The method of claim 13, wherein the composition is administered twice daily for at least 3 months.

15. The method of claim 14, wherein the composition is administered twice daily for at least 1 year.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc